Skip to Main Content

Paper Details

The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid.
Clin Microbiol Infect
2
2022
Author NameAffiliation
Simon TiberiBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Royal London Hospital, Barts Health NHS Trust
  • 1 - 1

Datasets

Release 1.2